Neural Noise

Sleep scoring in neurodegenerative diseases: towards new rules

2 min read

  • Sleep staging in neurodegenerative diseases is under review, with proposals for new scoring rules.1
  • The topic is relevant to EEG/sleep neurophysiology and indirect relevance to neural time-series and long-term monitoring.1 1

Weekly enrichment (2026-07-20)

  • This Clinical Neurophysiology review argues that standard AASM sleep scoring criteria often fail to accurately describe sleep architecture in patients with neurodegenerative diseases because of disease-related alterations in neurophysiological variables.2
  • The authors present an alternative sleep scoring system developed through collaboration between sleep centres in Bologna and Barcelona, specifically tailored to neurodegenerative disorders.2
  • The system adds stages that conventional international rules cannot classify: Abnormal Wake, Subwake, Undifferentiated NREM (UNREM), Poorly Structured N2 (P-S N2), REM without low-amplitude mixed-frequency activity (RWL), and REM without rapid eye movements (RWR).2
  • The method was tested on complex video-polysomnography recordings from nine patients with Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy, demonstrating excellent interrater agreement.2
  • The review builds on an earlier pilot study in the synucleinopathies (Montini et al., Sleep Medicine, 2023) of the same nine patients (four female, median age 74, range 63-85), where UNREM was present in all patients and was the most common stage in five, P-S N2 appeared only in the three MSA patients, and brief REM intrusions into NREM were termed “Encapsulated RBD”.3
  • The authors frame these detailed sleep-structure changes as potential dynamic, non-invasive biomarkers of neurodegeneration, relevant to long-term EEG monitoring and neural time-series analysis.2
  • The proposed rules are presented as promising but preliminary and requiring validation on a larger patient cohort.2
  • Prior work highlights why standard rules struggle here: an automatic scoring algorithm reproducing AASM criteria matched manual scoring for normals (about 87.7% agreement, Cohen’s kappa 0.79) but dropped to roughly 68.2% agreement (kappa 0.26) for Parkinson’s disease/MSA patients.4

Footnotes

  1. https://www.sciencedirect.com/science/article/pii/S1388245725007989?dgcid=rss_sd_all ↩ ↩2 ↩3

  2. https://pubmed.ncbi.nlm.nih.gov/40769811/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  3. https://pubmed.ncbi.nlm.nih.gov/37678074/ ↩

  4. https://doi.org/10.1097/wnp.0b013e3181eaad4b ↩

Graph View